Improving the physicochemical and pharmacokinetic properties of olaparib through cocrystallization strategy

Olaparib (OLA) is the first PARP inhibitor worldwide used for the treatment of ovarian cancer . However, the oral absorption of OLA is extremely limited by its poor solubility. Herein, pharmaceutical cocrystallization strategy was employed to optimize the physicochemical and pharmacokinetic properties. Four cocrystals of OLA with oxalic acid ( OLA-OA ), malonic acid ( OLA-MA ), fumaric acid ( OLA-FA ) and maleic acid ( OLA-MLA ) were successfully discovered and characterized. Fourier transform infrared spectroscopy and X-ray photoelectron spectroscopy confirmed the formation of cocrystals rather than salts, and the possible hydrogen bonding patterns were analyzed through molecular surface electrostatic potential calculations. The in vitro and in vivo evaluations indicate that all of the cocrystals demonstrate significantly improved dissolution performance, oral absorption and tabletability compared to pure OLA. Among them, OLA-FA exhibit sufficient stability and the most increased C max and AUC 0-24h values that were 11.6 and 6.1 times of free OLA, respectively, which has great potential to be developed into the improved solid preparations of OLA.